DRIVE-SHIFT Study: Switch to DOR/3TC/TDF in HIV Patients - Efficacy and Drug Resistance Analysis
The DRIVE-SHIFT study evaluated switching to DOR/3TC/TDF in HIV patients with suppressed viral loads. The study aimed to assess the efficacy of DOR/3TC/TDF compared to continuation of current antiretroviral therapy (cART) at both 24 and 48 weeks. Results showed non-inferiority of DOR/3TC/TDF in main
1 views • 7 slides
Comparison of NNRTI vs NNRTI and DRIVE-AHEAD Study: DOR/3TC/TDF vs EFV/FTC/TDF
The comparison study explores NNRTI regimens alongside the DRIVE-AHEAD trial, focusing on DOR/3TC/TDF vs EFV-FTC/TDF. DRIVE-AHEAD assesses the efficacy and safety of DOR in ARV-naïve HIV patients, aiming for non-inferiority based on virologic response, with DOR exhibiting potential neuropsychiatric
0 views • 11 slides
Switch to ATV/r + 3TC: ATLAS-M Study
The ATLAS-M Study focused on switching to ATV/r + 3TC in participants with specific criteria, aiming to assess non-inferiority compared to ATV/r + 2 NRTIs. Results at W48 indicated a higher proportion free of treatment failure with ATV/r + 3TC, with notable differences in virologic failure rates and
0 views • 7 slides